European of German nationality. Professor, ORL and allergist, @EAACI ExCom member, DGAKI ext. board of directors. Associate Editor Allergy
Marburg, Germany
Joined March 2020
- Tweets203
- Following107
- Followers272
- Likes72
Oliver Pfaar retweeted
Open Access: Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies. First and corresponding author: Oliver Pfaar
Read the article here: doi.org/10.1111/all.15723
The understanding of adherence or persistence to allergen immunotherapy (AIT) is hampered by a lack of specific guidance on appropriate clinical trial design. Pfaar et al. conducted a comprehensive review of current evidence and developed a checklist to enhance the design and reporting of trials evaluating adherence or persistence to AIT. The APAIT checklist is novel and highlights an important issue in the allergy field.
Read more articles published in #Allergy on allergen #immunotherapy here: journalallergy.com/Allergen-…
#Allergy_journal @OPfaar
Oliver Pfaar retweeted
Watch this message from @OPfaar - EAACI Congress Ambassador.
Join us in Hamburg for the #EAACICongress2023 , an event that will offer the latest scientific breakthroughs, networking opportunities and countless possibilities to transform healthcare.
➡️ow.ly/jRvN50MZ2xg
Oliver Pfaar retweeted
Extremely important new GRADE guidance for rating of imprecision, opening the door to much more frequent rating down two levels. Thanks to Linan Zeng, superb examples from the literature illustrate the guidance, making it crystal clear.
bit.ly/3PiTFfS
Oliver Pfaar retweeted
Making a distinction between evidence-based and consensus-based guidelines is both misguided and misleading: all trustworthy guidelines demand both rigorous evaluation of the evidence and a process to reach a panel consensus.
bit.ly/3cX623x
Oliver Pfaar retweeted
Kinder und Jugendliche: Könnt Ihr uns helfen,
Baumpollenallergien zu besiegen?
Oliver Pfaar retweeted
Fokkens et al., #Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis
Read the article here👉 doi.org/10.1111/all.15434
See more papers published in #Allergy on #CRSwNP here👉 journalallergy.com/Rhinitis-…
#Allergy_journal
Oliver Pfaar retweeted
The #originalarticle “#Allergenimmunotherapy in #MASK-air users in real-life: Results of a Bayesian mixed-effects model” published in the #CTA_Journal is available and #openaccess! 🔗Link: onlinelibrary.wiley.com/doi/… #allergen #bayesianmodel
Oliver Pfaar retweeted
Für #Allergologen: Sneak Preview zum 17. Deutschen #Allergiekongress: #MeinAllergiePortal im Interview mit Prof. Worm und Prof. Pfützner! youtu.be/rv3ge30qQSk
Oliver Pfaar retweeted
We are extremely proud to announce the journal’s new impact factor of 14.71, keeping #Allergy as the 1 journal in the field. This success has been possible with the excellent collaboration with our authors and reviewers, and outstanding #research. #asthma #sinusitis #dermatitis
Oliver Pfaar retweeted
🎦Nieto, et al. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual #immunotherapy
Read the article here👉doi.org/10.1111/all.15374
Watch more videos👉youtube.com/Allergy-TV
#Allergy_journal
youtube.com/watch?v=Rtnb5k2C…
Oliver Pfaar retweeted
🎦Sousa-Pinto, et al., Comparison of #rhinitis treatments using MASK-air® data and considering the Minimal Important Difference.
Read more👉 doi.org/10.1111/all.15371
Watch other videos from the journal 👉youtube.com/Allergy-TV
#Allergy_journal
youtube.com/watch?v=_KhSpCsj…
Oliver Pfaar retweeted
Heute ist #ClinicalTrials Day! In Deutschland bewertet und genehmigt das Paul-Ehrlich-Institut klinische Prüfungen von Impfstoffen & biomedizinischen Arzneimitteln.
Erfahren Sie im Video der @EMA_News, wie die EU deren Regulation verbessern will. 👇
youtube.com/watch?v=z9i9k2Zh…
Oliver Pfaar retweeted
Sokolowska et al. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: #EAACI task force on eicosanoids consensus report in times of #COVID19.
Read 👉 doi.org/10.1111/all.15258
youtube.com/watch?v=9-h_tFmx…
Oliver Pfaar retweeted
Open Access: Pfaar, O., Agache, I., Bonini, M., et al. COVID-19 pandemic and allergen immunotherapy—an EAACI survey. Allergy. 2021; 76: 3504-3516. doi.org/10.1111/all.14793
Oliver Pfaar retweeted
#MustRead: Perceptions of #adolescents & young adults with #allergy and/or #asthma & parents on EAACI recommendations about transitional care @AllergyEaaci @KateKhaleva @DunnGalvin @marta_allergy @pascomber @elizabethangier @OPfaar @alex_fsantos @Ana_Filaxia @ProfGRoberts👏
Oliver Pfaar retweeted
Free Access: One hundred and ten years of #AllergenImmunotherapy: A journey from empiric observation to evidence. First and corresponding author: Oliver Pfaar @OPfaar Read the article here👉 bit.ly/2W1EeTC
journalallergy.com
Oliver Pfaar retweeted
🎦Our Editor-in-Chief Dr. Cezmi Akdis @AkdisCezmi celebrates the new impact factor (13.15) and highlights the achievements and novel changes in #Allergy during the last three years after our team took over. journalallergy.com youtu.be/QGvHulyxDBU
Oliver Pfaar retweeted
Top story: @allergyuptodate: '𝗟𝗮𝘁𝗲𝘀𝘁 𝗶𝗺𝗽𝗮𝗰𝘁 𝗳𝗮𝗰𝘁𝗼𝗿 𝗳𝗼𝗿 𝗔𝗹𝗹𝗲𝗿𝗴𝘆 𝗝𝗼𝘂𝗿𝗻𝗮𝗹𝘀 - 𝗧𝗼𝗽 𝟭𝟱. @clarivate @webofscience #allergy #journals #impact_factor ' xitter.cf/allergyuptodate/status…, see more tweetedtimes.com/Aller_MD?s=…
